Lombard Medical PT Lowered to $11.00 at Barclays (EVAR)
Analysts at Barclays cut their price objective on shares of Lombard Medical (NASDAQ:EVAR) from $12.00 to $11.00 in a research report issued to clients and investors on Thursday. Barclays’ target price points to a potential upside of 76.85% from the company’s current price.
EVAR has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Lombard Medical in a research note on Tuesday, July 29th. They set an “outperform” rating on the stock.
Lombard Medical (NASDAQ:EVAR) opened at 6.22 on Thursday. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.. The company’s market cap is $100.7 million.
Lombard Medical (NASDAQ:EVAR) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.86) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.52) by $0.34.
Lombard Medical, Inc is a medical technology company specializing in developing, manufacturing, and marketing endovascular stent-grafts.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.